Background Familial cases of appendiceal mucinous tumours (AMTs) are extremely rare and the underlying genetic aetiology uncertain. We identified potential predisposing germline genetic variants in a father and daughter with AMTs presenting with pseudomyxoma peritonei (PMP) and correlated these with regions of loss of heterozygosity (LOH) in the tumours.
background Appendiceal mucinous tumours (AMTs) are rare, occurring at an age-adjusted incidence of 0.12 per million individuals, with a median age at diagnosis of 59 years and no gender bias(1). Pseudomyxoma peritonei (PMP) is a clinical term describing gelatinous ascites, associated with the presence of mucin-producing cells within the peritoneal cavity, usually associated with an appendiceal mucinous neoplasm, either a low-grade appendiceal mucinous neoplasm (LAMN) or a mucinous adenocarcinoma(2). Whether PMP occurs in all, or just a molecular subset of AMTs is unknown.
Molecular studies of PMP are limited, but somatic mutations have been identified in KRAS in 60-100% of tumours, in GNAS in 30-69% of tumours and in TP53 in ~14% of tumours(3-8). The reported frequency of somatic mutations in the APC gene varies widely between studies ranging between 0-33% (4, 7).
Familial forms of AMTs are rare, with only two reported cases in the literature. The first family comprised monozygotic twin brothers (9). The first twin was diagnosed with PMP at the age of 35 during an umbilical hernia repair, and he was subsequently found to have a perforated AMT. After this diagnosis, his asymptomatic twin underwent a prophylactic appendectomy which identified a nonperforated AMT. Somatic loss of heterozygosity (LOH) of the APC locus was identified in the second AMT but not in the original case. No germline APC mutation data were available.
The second family comprised a brother and sister diagnosed with AMTs at the ages of 69 and 77 years respectively(10). The brother presented with acute appendicitis and an AMT was identified at surgery, while his sister presented with increasing abdominal girth and was found to have PMP and an AMT. An assessment for Lynch syndrome was performed in this family. The sister's AMT had normal immunohistochemistry staining for the mismatch repair proteins MLH1, MSH2, MSH6 and PMS2,and her tumour was microsatellite stable, whilst her brother underwent constitutional mutation analysis of MLH1, MSH2 and MSH6 which did not identify a pathogenic variant.
Here, we report the first familial parent-child PMP case, a father (P1) and daughter (P2) who were both diagnosed with PMP secondary to an AMT at the ages of 66 and 51 years respectively. P1 was incidentally found to have PMP on staging CT for a Identifying the germline genetic aetiology of rare familial colorectal cancer syndromes such as familial adenomatous polyposis has led to a better understanding of many somatic pathways and mechanisms underlying sporadic forms of the disease. Thus, we sought to identify predisposing genes in this family through a germline whole exome sequencing approach and looked for regions of LOH in their tumour tissues as a secondary filter for potentially pathogenic variants.
Materials and Methods

Ethics
All procedures performed involving human participants were in accordance with the ethical standards of the Peter MacCallum Cancer Centre Human Research and Ethics Committee (project number 10_83) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
Whole exome sequencing
One µg of germline DNA was obtained from peripheral leucocytes and fragmented using the Covaris S2 System (Covaris, Woburn, MA, USA). The SureSelect Human All Exon v1 (Agilent, Santa Clara, CA, USA) was used for exome enrichment according to the manufacturer's protocol. Paired-end 100 base pair reads were sequenced on a HiSeq2000 (Illumina Inc, San Diego, CA, USA) instrument. Both exomes passed sequencing quality control with mean target base coverages of 129x and 121x for P1 and P2 respectively and >95% of targeted bases covered more than 10x.
Sequence alignment and variant calling
Raw sequence reads were quality checked with FastQC(11) and trimmed for low quality bases and adaptor if necessary using Cutadapt (12) . Reads were aligned to the human genome (GRCh37 assembly) using BWA-MEM (13) . Duplicate reads were marked using Picard(14) followed by merging of BAM files for both individuals. Local realignment around indels was performed on the merged BAM files using the Genome Analysis Tool Kit (GATK) software v3.1 (15) . Subsequently, base quality score recalibration was performed using GATK software. Single nucleotide variants (SNVs) and indels were identified using the GATK HaplotypeCaller and annotated with information from Ensembl release 73 using Ensembl's Perl API and Variant Effect Predictor (16, 17) . Each variant was annotated with its frequency in the 1000 Genomes Project (18) , the National Heart, Lung and Blood Institute (NHLBI) Grand Opportunity (GO) Exome Sequencing Project (19) and an in-house exome dataset of 147 familial breast cancer cases (20) . The likely pathogenic consequence for each variant was determined by Polyphen (21) , SIFT (22) , and Combined Annotation Dependent Depletion (CADD) scaled score(23).
Exome data analysis
For genes with multiple transcripts, transcripts were prioritised on 1) most to least deleterious predicted impact of variant on protein function (Supplementary Data 1), and 2) RefSeq transcript. The highest ranking transcript was taken forward for further analysis. LoF variants and missense variants which met the following criteria were considered for further analysis: (1) Phred variant quality score of >30, and (2) variant allele frequency between 0.15 and 0.8. For identification of novel variants shared between P1 and P2, variants were excluded if they were present in control cohorts: 1000 Genomes Project, NHLBI GO Exome Sequencing Project or an in-house cohort of 147 Australian familial breast cancer exomes. All loss of function (LoF) variants (truncating frameshift, nonsense, essential splice site), and missense variants with a CADD scaled score ≥10 were manually checked in the Integrated Genome Viewer (IGV) (24, 25) .
Variants shared between P1 and P2 which were confirmed on Sanger sequencing were checked in the Exome Aggregation Consortium (ExAC) dataset, a dataset comprising exome data from 60,706 unrelated individuals (26) , for the population frequency, to confirm that these variants were rare or novel.
Whole genome amplification and Sanger sequencing
Candidate variants were confirmed by Sanger sequencing using whole-genome amplified DNA from P2. Whole-genome amplification of genomic DNA was performed using the REPLI-g Midi Kit (Qiagen, Redwood City, CA, USA). PCR primers were designed using the Primer3 program v0.4.0 (27, 28) and are listed in Supplementary Data 2. DNA fragments were amplified using HotStarTaq DNA Polymerase (Qiagen, Redwood City, CA, USA), purified using ExoSAP-IT PCR Purification Kit (USB Corporation, Cleveland, OH, USA), and sequenced using the Big Dye Terminator v3.1 kit (Applied Biosystems, Foster City, CA, USA). Sanger sequencing was performed on an ABI3130 Sequencer (Applied Biosystems), and visualised in Geneious 5.6.2 software (BioMatters Ltd, Auckland, New Zealand).
Tumour micro-dissection and analysis
Both tumours were reviewed by a clinical pathologist with expertise in this area.
Consecutive 10 μm sections were cut from the formalin fixed paraffin embedded PMP specimens with the highest tumour content, and stained with haematoxylin and eosin. Tumour cells were micro-dissected manually using a 23 gauge needle and somatic DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen, Redwood City, CA, USA). Somatic copy number analysis of tumours was assayed using the OncoScan Molecular Inversion Probe assay (Affymetrix, Santa Clara, CA, USA) on 50-75 ng of somatic DNA, and the data analysed using Nexus Copy Number TM software (Biodiscovery, Inc., El Segundo, CA, USA). There was no matched control copy number data available for P2. The Oncoscan molecular assay comprises >220,000 single nucleotide polymorphisms and provides copy number resolution around 50-100 kb.
To assess if a variant showed somatic LOH, Sanger sequencing was performed using unamplified tumour DNA extracted from the AMT (primers listed in Supplementary Data 3).
Sanger sequencing of candidate genes in a PMP validation cohort
Germline DNA from individuals with sporadic PMP was obtained from the Victorian Cancer Biobank (VCB), the Australian Ovarian Cancer Study (AOCS) and Southampton, UK(29). Histopathology reports for all PMP samples in the validation cohort were examined to ensure that they were not metastases of ovarian origin.
Sanger sequencing of all exons of REEP5 was performed using germline DNA from individuals from the PMP validation cohort, using the same methods as 
Results
Analysis of genes associated with known familial colorectal cancer syndromes Prior to analysis for novel shared germline variants, a targeted analysis was undertaken of 17 genes associated with an increased familial colorectal cancer risk:
APC, MUTYH, MLH1, MSH2, MSH6, PMS2, BMPR1A, SMAD4, STK11, EPCAM(30), GREM1, POLE(31), POLD1(31), BUB1(32), BUB1B(33), BUB3(32) and NTHL1(34). All these genes excluding STK11 were sequenced with a mean coverage of > 68X (Supplementary Data 5). No LoF or known pathogenic missense variants were identified in either case. A rare missense variant in POLE carried by both P1 and P2 was identified, POLE p.Val1887Met (NM_006231.2:c.5659C>T). This variant has an allele frequency of 6.15X10 -4 in the NHLBI GO Exome Sequencing Project. This POLE variantdid not fall in a region of LOH in either P1 or P2. Using in-silico prediction tools, this variant had a CADD score of 10.07, but was predicted non-pathogenic by both SIFT and PolyPhen.
Identification of shared germline variants
LoF and missense variants with an allele frequency between 0.15 and 0.8 were selected in order to identify heterozygous variants. A total of 4,893 and 4,973 variants were identified in P1 and P2, respectively. After excluding any variant previously reported in the 1000 Genomes Project or the NHLBI GO Exome Sequencing Project, or a local cohort of 147 familial breast cancer exomes, a total of 106 and 110 variants remained in P1 and P2, respectively. Of these, 40 variants (8 LoF and 32 missense) were shared between P1 and P2. Manual curation of the variant reads in IGV eliminated a further 9 variants as likely artefacts due to misalignment, known hypervariable genes or variants located in areas with low mapping quality. Missense variants were prioritised on their CADD score. A CADD scaled score of ≥10 was used as an inclusion threshold, as this identifies the top 10% most deleterious substitutions in the human genome (23) . This approach eliminated a further seven missense variants. Following validation by Sanger sequencing, the final list of shared variants in 17 genes comprised 2 LoF and 15 missense variants (Table 1 ). The number of variants remaining after each filtering step is summarised in Supplementary Data 6.
Identification of germline variants associated with concomitant areas of tumour LOH
Assuming a possible two-hit model for germline tumour suppressor inactivation, analysis was performed to identify germline candidate variants present in regions of LOH in the tumours.
The Oncoscan array detected somatic LOH (copy number neutral and loss) in 20.3% and 19.8% of the tumour genomes of P1 and P2, respectively (Tables 2 and 3 ). Only one region of LOH, a 1.77 Mb region on chromosome 2q, was common to both tumours ( Fig. 3 ). This region contains 33 genes but none harboured likely pathogenic germline variants common to both individuals.
As LOH is not the only mechanism by which a somatic wild type allele can be abrogated, the analysis was extended to incorporate all regions of somatic LOH present in either P1 or P2's tumour. Missense variants in four genes, EXOG, RANBP2, RANBP6 and TNFRSF1B, were identified in areas of LOH seen in the tumour from P1.
The LOH regions in the tumour from P2 did not harbour any shared germline variants.
The variants in EXOG, RANBP2, RANBP6 and TNFRSF1B were sequenced in the tumour DNA of P1 to assess which allele of the gene was lost. We took an agnostic approach to identifying the causative gene by identifying novel (ie. not present in the 1000 Genomes Project and NHLBI GO Exome Sequencing Project datasets) shared germline variants in the exome of both individuals, coupled with genome-wide copy number analysis of both tumours. We identified 17 potentially pathogenic variants shared between the two cases, including four within regions of LOH in the father's tumour. Loss of the potentially pathogenic missense variant in RANBP2 in the tumour genome, suggests this variant is unlikely to be the cause of the PMP predisposition. The missense variants in EXOG, RANBP6 and TNFRSF1B remained heterozygous in the primary tumour of P1, although with the loss of the second allele at a later stage, this does not necessarily exclude these variants as possible PMP predisposition genes on these data alone.
A shared nonsense variant in REEP5 p.Tyr53* (NM_005669.4:c.159T>G) would appear to be a strong candidate as the predisposing variant, although both tumours retained heterozygosity at this locus. REEP5 has been implicated in the regulation of TP53, a known cancer predisposition gene,through its interaction with HCCR1 (36, 37) . It is expressed in normal colonic tissue and has been shown to be downregulated in colon cancers. Similarly, transfection of REEP5 into RKO colon cancer cells results in growth inhibition and induction of apoptosis, suggesting it functions as a tumour suppressor (36) . REEP5 is also involved in stabilisation of the endoplasmic reticulum tubules via its effect on the curvature of the endoplasmic reticulum lipid bilayer (38) . The lack of REEP5 mutations in the 23 sporadic PMP cases that were screened suggests that germline REEP5 mutations are not common in sporadic PMP.
THOP1, which harboured a shared essential splice site variant, is an oligopeptidase involved in metabolism of neuropeptides such as bradykinin (39) . Increased THOP1 expression in background liver is associated with improved survival post resection of hepatocellular carcinoma(40), suggesting a possible tumour suppressive effect.
Several genes that contained a shared rare missense variant have functions consistent with cancer predisposition. RHBDL2 is a rhomboid intra-membrane protease that activates epidermal growth factor and is associated with anoikis resistance (41) . FGFR4 is part of the fibroblast growth factor receptor family, a subset of tyrosine kinase receptors that are highly conserved. The fibroblast growth factor receptors have been extensively investigated somatically in relation to various cancers, and several fibroblast growth factor receptor inhibitors are in clinical trials (42) . The 
Study limitations
This study only searched exon-based sequences and as such would be unable to identify sequence variants present in gene regulatory regions. The aggregation of PMP within the family may also have arisen due to a shared environmental factor, or due to stochastic events. PMP is a hypo-cellular tumour with only widely scattered groups of tumour cells in abundant mucin. This phenotype provided technical problems in the somatic LOH analysis. conclusions Through germline whole exome sequencing of a very rare familial occurrence of a very rare cancer type, in which only 2 families with limited genomic analyses have been reported in the literature, our study makes several contributions to knowledge.
We have identified candidate variants that may predispose to the development of AMTs and PMP in this family. We were also able to examine the known CRCpredisposing genes (apart from STK11) and found no pathogenic variants in this family, suggesting that other novel genes may predispose to this rare subtype of cancer in the colon. Through the re-sequencing of REEP5 in 23 sporadic PMP cases, we found that REEP5 mutations are not a common cause of sporadic PMP despite a 
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